John Santini, President and CEO of Vergent Bioscience
Tiny Vergent seals modest Series B in pursuit of cancer imaging agent
A biotech with only two full-time employees now has millions of more dollars to spend in its work on an imaging molecule.
Based out of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
